导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.95% | 1082/4773 |
| 近一周 | 0.12% | 378/5458 |
| 近一月 | 2.30% | 370/5421 |
| 近一季 | 1.84% | 606/5205 |
| 近半年 | -1.65% | 1874/4920 |
| 近一年 | 7.35% | 1473/4361 |
| 近两年 | 35.68% | 2108/2954 |
| 近三年 | 24.22% | 1329/2253 |
| 成立以来 | 155.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.91% 634/4961 |
-9.12% 3943/5312 |
- - |
- - |
| 2025 | 6.85% 2941/4813 |
-2.21% 2861/3635 |
3.12% 1148/4076 |
3.05% 3773/4524 |
2.82% 839/4813 |
| 2024 | 14.84% 994/3463 |
3.52% 552/2808 |
2.05% 408/3014 |
9.36% 2705/3129 |
-0.60% 1476/3463 |
| 2023 | -1.34% 505/2656 |
3.08% 1269/2280 |
-2.18% 564/2385 |
1.46% 308/2515 |
-3.56% 723/2655 |
| 2022 | 6.76% 13/2207 |
5.63% 29/1919 |
5.86% 814/2016 |
-1.44% 23/2113 |
-3.14% 1837/2208 |
| 2021 | 17.39% 234/1822 |
5.29% 114/1255 |
3.76% 957/1330 |
12.44% 98/1466 |
-4.44% 1484/1822 |
| 2020 | 23.71% 645/1250 |
-6.92% 516/1028 |
9.05% 803/1067 |
13.26% 331/1164 |
7.60% 703/1184 |
| 2019 | 29.85% 493/1092 |
22.80% 569/754 |
-4.07% 418/804 |
0.47% 515/850 |
9.71% 206/918 |
| 2018 | - - |
- - |
- - |
- - |
-3.84% 25/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 西部利得国企红利指数增强A VS. 长安沪深300非周期A(740101) |